Frontlight ResearchEarly access
Taking peoplePhase 2/3
Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULCANize2)
Key facts
- Who runs it
- Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis
- Where
- Belgium, Czechia, Netherlands, and Spain10 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 98 people, planned
- Started
- 1 Jan 2024
- Expected to end
- 30 Jun 2029
- Type of study
- Interventional
- Record updated
- 2 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Woman ≥ 18 years
- Beta HCG level of 14 mIU/mL or below for women of childbearing potential
- Highly effective contraception for patients if the risk of conception exists
- Highly effective contraception for patients if the risk of conception exists
- Signed and written informed consent
- Histologically-confirmed primary or recurrent squamous cell carcinoma vulvar cancer FIGO stage Ib – IVa, T1b or higher, any N, M0
- Local tumour through which the size or localization implies requirement of treatment through primary chemoradiation or surgery consisting of extensive surgery (meaning surgery damaging pelvic organs or exenterative surgery). This can imply: T1b or larger tumour with (irresectable) groin metastases. Or this can imply: T1b or larger tumour with a close relationship to and/or involvement of the urethra or anal sphincter
- World Health Organization performance status of 0‐2
- Adequate haematological function defined by platelet count >100x10E9/L, absolute neutrophil count >1.5x10E9/L, and hemoglobin >6.0 mmol/L
- Adequate hepatic function defined by a total bilirubin level ≤1.5x the upper limit of normal range and ASAT and ALAT levels ≤2.5x ULN for all subjects
- Adequate renal function defined by an estimated creatinine clearance ≥50mL/min according to the Cockroft-Gault formula (or local institutional standard method)
Who cannot take part
- Prior radiotherapy to the pelvis or groin area limiting full dose chemoradiation according to protocol
- Existing neuropathy which will hinder the intake of chemotherapy
- Any psychiatric condition that would prohibit the understanding or rendering of informed consent
- Patients with highly suspicious or positive metastases to the pelvic lymph nodes
- Patients eligible for radical local excision without involvement of other organs
- Contra-indication to paclitaxel, cisplatin or carboplatin as stated in the SmPC
This trial is currently available in Belgium, Czechia, and Netherlands.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objective of this trial is to compare the efficacy and safety of primary chemoradiation with neoadjuvant chemotherapy (NACT) followed by surgery in patients with LAVC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 2 June 2026